Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Newly Diagnosed Ph+ CML-CP
NCT01227577Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Nov 2010; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01227577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01227577.